Format

Send to

Choose Destination
J Pharm Sci. 2010 Dec;99(12):4940-54. doi: 10.1002/jps.22217.

The developability classification system: application of biopharmaceutics concepts to formulation development.

Author information

1
Pharmaceutical Development, GlaxoSmithKline R&D, Harlow, UK. james.m.butler@gsk.com

Abstract

A revised classification system for oral drugs was developed using the biopharmaceutics classification system (BCS) as a starting point. The revised system is designed to have a greater focus on drug developability. Intestinal solubility, the compensatory nature of solubility and permeability in the small intestine and an estimate of the particle size needed to overcome dissolution rate limited absorption were all considered in the revised system. The system was then validated by comparison with literature on the in vivo performance of a number of test compounds. Observations on the test compounds were consistent with the revised classification, termed the developability classification system (DCS), showing it to be of greater value in predicting what factors are critical to in vivo performance than the widely used BCS.

PMID:
20821390
DOI:
10.1002/jps.22217
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center